Healthcare / Medical DevicesStockholm
$21.00
+1.00 (+5.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 24%
FCF escenarios
weak_data · normalized FCF $-41.4M · quality 72.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
35/100
D
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$178M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-56.8%
↓Gross Margin
N/A
•Debt/Equity
0.07
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
—
FCF / Net income
1.24x
Latest source
Provider fallback
Margin decomposition
Último año: revenue — · net income $-35.5M · FCF $-44.0M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | — | — | — | — | $10000.00 |
| Net Income | $-35.5M | $-35.5M | $-34.4M | $-68.0M | $-14.0M |
| EBITDA | $-34.9M | $-34.9M | $-33.5M | $-67.3M | $-13.7M |
| EPS | -7.08 | -7.08 | -16.55 | -46.79 | -18.79 |
| Gross Margin | — | — | — | — | 122872.7% |
| Operating Margin | — | — | — | — | -128463.2% |
| Net Margin | — | — | — | — | -139879.1% |
| Balance Sheet | |||||
| Debt/Equity | 0.07 | 0.07 | 0.09 | 0.10 | 0.02 |
| Current Ratio | 2.50 | 2.50 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-44.0M | $-44.0M | $-41.4M | $-26.8M | $-31.1M |
| Returns | |||||
| ROE | -56.8% | -56.8% | -51.0% | -82.9% | -14.3% |
| Valuation | |||||
| P/B | 1.69 | 1.69 | 0.36 | 0.70 | 1.04 |
| Growth & Yield | |||||
| EPS Growth | 57.2% | 57.2% | 64.6% | -149.0% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+47.4%
Start / end P/E
n/dx → n/dx
EPS bridge
-16.55 → -7.08
Residual
+47.4%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.